MEFENAMIC ACID

Post-LOE

mefenamic acid

Molecular Devices

ANDAORALCAPSULE

Approved

Nov 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

MEFENAMIC ACID (mefenamic acid) by Molecular Devices is cyclooxygenase inhibitors [moa]. Approved for mild to moderate pain in adults, older, therapy will not exceed one week (7 days) and 1 more indications. First approved in 2010.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (4)

mild to moderate pain in adults older

Worked on MEFENAMIC ACID at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (3)

NCT05064449Phase 1Completed

A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults

Started Oct 2021

28 enrolled

Healthy Volunteers

NCT03070678Phase 1Completed

Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects

Started Mar 2017

16 enrolled

Diabetes Mellitus

NCT02183025Phase 2Completed

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Started Jan 1998

337 enrolled

Dysmenorrhea